You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 2, 2024

Claims for Patent: 10,105,374

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,105,374

Title:	Controlled release and taste masking oral pharmaceutical compositions
Abstract:	The invention relates to tablet comprising granules dispersed in at least one hydrophilic compound or matrix. The granules contain an active agent, at least one amphiphilic compound and at least one lipophilic compound. The tablet may include a gastro-resistant film coating.
Inventor(s):	Villa; Roberto (Lecco, IT), Pedrani; Massimo (Gignese, IT), Ajani; Mauro (Milan, IT), Fossati; Lorenzo (Milan, IT)
Assignee:	COSMO TECHNOLOGIES LIMITED (Dublin, IE)
Application Number:	15/646,538
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,105,374
Patent Claims:	1. A controlled release oral pharmaceutical composition consisting essentially of: (1) a tablet core consisting of a matrix comprising: a) budesonide in an amount to treat intestinal inflammation; b) magnesium stearate, stearic acid, or a mixture thereof; c) hydroxyalkyl cellulose; and d) optionally starch or a starch derivative; and (2) a coating on said tablet core, said coating consisting essentially of a gastro-resistant film. 2. The controlled release oral pharmaceutical composition according to claim 1, wherein said matrix comprises magnesium stearate. 3. The controlled release oral pharmaceutical composition according to claim 1, wherein said matrix comprises stearic acid. 4. The controlled release oral pharmaceutical composition according to claim 1, wherein said matrix comprises starch. 5. The controlled release oral pharmaceutical composition according to claim 4, wherein said matrix comprises magnesium stearate. 6. The controlled release oral pharmaceutical composition according to claim 4, wherein said matrix comprises stearic acid. 7. The controlled release oral pharmaceutical composition according to claim 1, wherein said matrix comprises a starch derivative. 8. The controlled release oral pharmaceutical composition according to claim 7, wherein said matrix comprises magnesium stearate. 9. The controlled release oral pharmaceutical composition according to claim 7, wherein said matrix comprises stearic acid. 10. The controlled release oral pharmaceutical composition according to claim 1, wherein said gastro-resistant film comprises methacrylic acid polymer. 11. The controlled release oral pharmaceutical composition according to claim 2, wherein said gastro-resistant film comprises methacrylic acid polymer. 12. The controlled release oral pharmaceutical composition according to claim 3, wherein said gastro-resistant film comprises methacrylic acid polymer. 13. The controlled release oral pharmaceutical composition according to claim 4, wherein said gastro-resistant film comprises methacrylic acid polymer. 14. The controlled release oral pharmaceutical composition according to claim 5, wherein said gastro-resistant film comprises methacrylic acid polymer. 15. The controlled release oral pharmaceutical composition according to claim 6, wherein said gastro-resistant film comprises methacrylic acid polymer. 16. The controlled release oral pharmaceutical composition according to claim 7, wherein said gastro-resistant film comprises methacrylic acid polymer. 17. The controlled release oral pharmaceutical composition according to claim 8, wherein said gastro-resistant film comprises methacrylic acid polymer. 18. The controlled release oral pharmaceutical composition according to claim 9, wherein said gastro-resistant film comprises methacrylic acid polymer. 19. A method for treating intestinal inflammatory disease in a patient, comprising administering to the patient the controlled release oral pharmaceutical composition according to claim 1. 20. A method for treating intestinal inflammatory disease in a patient, comprising administering to the patient the controlled release oral pharmaceutical composition according to claim 2. 21. A method for treating intestinal inflammatory disease in a patient, comprising administering to the patient the controlled release oral pharmaceutical composition according to claim 3.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.